A Phase 2, randomized, double-blind trial to evaluate the safety, tolerability, and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Clinical Trial Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
July 16, 2024
End Date
July 15, 2025
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
July 16, 2024
End Date
July 15, 2025